Trial Profile
Clinical Trials Insight: 700057610
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Vilanterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 19 May 2010 Study results were reported at the 106th International Conference of the American Thoracic Society.
- 19 May 2010 New trial record